secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pediatrix Medical Group, Inc. (MD)
CIK:        0000893949
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0000950170-24-119795
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pediatrix Q3 adjusted EPS $0.44, revenue $511M; reaffirms FY 2024 EBITDA guidance $205-215M
--------------------------------------------------------------------------------

- Net revenue $511M, up from $506.6M YoY; same-unit revenue grew 5.2% (reimbursement +3.4%, volume +1.8%).
- GAAP EPS $0.23, down from $0.26 YoY; Adjusted EPS $0.44 vs $0.32; Adjusted EBITDA $60M vs $50.4M.
- Exiting almost all office-based practices (except maternal-fetal medicine); expects ~$30M annualized EBITDA benefit by year-end.
- Cash from operations $95.7M; total debt $619M, no revolver borrowings; completed hybrid RCM transition.
- FY 2024 Adjusted EBITDA guidance $205-215M, implying Q4 roughly $50-60M based on YTD result of $155.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/893949/000095017024119795/0000950170-24-119795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/893949/000095017024119795/md-20241101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-119795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer